Nicotinamide-Riboside

Nicotinamide riboside (NR) is a pyridine nucleoside form of vitamin B3 and a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), the essential redox cofactor and sirtuin/PARP cosubstrate whose decline with aging is implicated in mitochondrial dysfunction, genomic instability, neurodegeneration, and metabolic disease. First identified as an NAD+ precursor in yeast by Bieganowski and Brenner in 2004 [1], NR is phosphorylated by the conserved nicotinamide riboside kinases NRK1 and NRK2 to nicotinamide mononucleotide (NMN), which is subsequently adenylylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to yield NAD+. This two-step pathway is independent of the Preiss-Handler and de novo biosynthetic routes and constitutes a distinct salvage mechanism for NAD+ repletion.

The compound attracted broad scientific attention following the 2012 demonstration by Canto, Houtkooper, Auwerx, and colleagues that dietary NR supplementation in mice activates SIRT1 and SIRT3, enhances mitochondrial oxidative metabolism, and protects against high-fat-diet-induced obesity and metabolic dysfunction [2]. Subsequent preclinical work established NR-mediated NAD+ repletion as protective in mouse models of dilated cardiomyopathy [3], noise-induced hearing loss, Alzheimer-like neurodegeneration, Parkinson disease [4], hepatic steatosis, muscular dystrophy, and age-related stem cell decline. In each case, the proposed mechanism centers on restoration of NAD+-dependent sirtuin and poly(ADP-ribose) polymerase activity in metabolically stressed tissues.

Translation to humans began with the Trammell et al. (2016) pharmacokinetic study demonstrating dose-dependent elevation of the blood NAD+ metabolome after single oral doses of 100, 300, and 1,000 mg in healthy volunteers [5]. The Martens et al. (2018) crossover trial in healthy middle-aged and older adults confirmed that chronic NR supplementation at 1,000 mg daily for six weeks is well tolerated, elevates whole-blood NAD+ by approximately 60 percent, and produces a trend toward reduced systolic blood pressure and aortic stiffness [6]. The Conze, Brenner, and Kruger (2019) eight-week randomized trial in 140 healthy overweight adults established dose-dependent (100, 300, 1,000 mg daily) and sustained NAD+ elevation with no detectable adverse effect on hepatic, renal, or lipid parameters [7]. The Elhassan et al. (2019) study demonstrated that NR augments the aged human skeletal muscle NAD+ metabolome and induces anti-inflammatory transcriptomic signatures [8]. More recently, the NADPARK trial (Brakedal et al. 2022) showed that NR at 1,000 mg daily for 30 days is well tolerated in newly diagnosed Parkinson disease patients, increases cerebral NAD levels measured by phosphorus magnetic resonance spectroscopy, and is associated with altered cerebral metabolism and mild clinical improvement in a subset of responders [4]. The NR-SAFE trial (2023) extended the safety assessment to 3,000 mg daily for 30 days in Parkinson disease patients, confirming tolerability and up to five-fold blood NAD+ elevation without methyl donor depletion [9].

Despite consistent pharmacodynamic evidence that oral NR elevates NAD+ in blood, muscle, and brain, clinically meaningful efficacy endpoints have proven elusive in most completed trials. NR has not demonstrated significant effects on insulin sensitivity, whole-body glucose metabolism, or skeletal muscle mitochondrial bioenergetics in randomized controlled trials in obese or older adults [10, 11]. Cognitive endpoints have not reached significance in trials of mild cognitive impairment [12]. The compound is therefore positioned as a well-tolerated NAD+ repletion agent with strong preclinical rationale, consistent pharmacodynamic activity, and an incomplete clinical efficacy record that awaits adequately powered Phase 2 and Phase 3 trials in disease-specific populations.

Nicotinamide riboside chloride is marketed as the dietary supplement Niagen (ChromaDex/Niagen Bioscience) and has received Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration for use as a vitamin B3 source in foods [13], as well as two successful New Dietary Ingredient notifications for use in dietary supplements. The compound is not approved as a drug for any indication. This monograph reviews the chemistry, biosynthetic pathway, molecular pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, adverse-event profile, and a comparative assessment of five NAD+ precursor and booster candidates against NR on five competency standards.